Disease

From Herceptin to Rozlytrek: how cancer drugs are getting more personalized

  • September, 25 2019
  • 1115

In August 2019, the US FDA approved Roche’s Rozlytrek (entrectinib) for cancer patients whose solid tumors harbor a particular genetic mutation called NTRK. The approval comes more than 20 years after the very first ‘targeted’ breast cancer therapy reache

Disease

As Rare Disease Drugs Multiply, So Must Creative Ways to Pay for Them

  • February, 19 2019
  • 784

Patients suffering from one of the many hundreds of rare diseases known to exist have a better chance than ever of finding a treatment. Companies large and small continue to invest, given high unmet need and very targeted populations. Progress must contin